<DOC>
	<DOCNO>NCT01856556</DOCNO>
	<brief_summary>The primary objective study evaluate safety tolerability single intravenous ( IV ) oral ( PO ) ascend dose NRX-1074 evidence incidence severity adverse event ( AEs ) , change serum chemistry , hematology , urinalysis , change physical examination finding subject-reported symptom . The secondary objective study assess plasma cerebrospinal fluid ( CSF ) pharmacokinetics ( PK ) , oral bioavailability experimental formulation renal elimination urine concentration NRX-1074 24 hour follow dosing .</brief_summary>
	<brief_title>Safety Pharmacokinetics NRX-1074 Normal Volunteers</brief_title>
	<detailed_description>Randomized , double-blind , placebo-controlled , single ascend dose level study . On Day 1 , eligibility subject confirm , physical examination perform , blood urine laboratory obtain . Each subject randomize , receive either single IV , SC IN dose GLYX-13 placebo .</detailed_description>
	<criteria>1 . Male female subject 2 . Aged 18 55 year 3 . For female subject , surgically sterile least 2 year menopausal , use acceptable method birth control date screen least 30 day last dose study drugIf childbearing potential , documented negative blood urine pregnancy test within 24 hour prior dose . 4 . Clinical laboratory value less equal 2 time upper limit normal ( ULN ) deem clinically significant Investigator . 5 . Ability understand requirement study , provide write informed consent , abide study restriction , agree return require assessment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>